H3T3A mutant protein efficiently reduces H3T3P and causes increased cell death of rapidly dividing cells
10639349 ยท 2020-05-05
Assignee
Inventors
Cpc classification
A61K45/06
HUMAN NECESSITIES
C07K2317/73
CHEMISTRY; METALLURGY
A61P35/00
HUMAN NECESSITIES
International classification
A61K39/395
HUMAN NECESSITIES
A61P35/00
HUMAN NECESSITIES
A61K45/06
HUMAN NECESSITIES
Abstract
The invention features compositions comprising an H3T3A mutant protein. Described herein are methods of inducing cell death in a rapidly dividing cell comprising contacting a rapidly dividing cell with an agent that reduces phosphorylation at threonine 3 of histone 3 (H3T3P), thereby inducing cell cycle arrest followed by cell death. In some cases, the rapidly dividing cell is a tumor cell, e.g., a cancer cell. The agent that reduces phosphorylation of H3T3P comprises an H3T3A mutant protein, e.g., a mutant transgenic protein. Described herein is a kit for arresting cell cycle comprising an agent that reduces phosphorylation H3T3P.
Claims
1. A method of inducing cell death in a rapidly dividing cell comprising: contacting a rapidly dividing cell with an agent that reduces phosphorylation at threonine 3 of histone 3 (H3T3P), thereby inducing cell cycle arrest followed by cell death, wherein the agent that reduces phosphorylation of H3T3P comprises an H3T3A mutant protein or an H3T3D mutant protein.
2. The method of claim 1, wherein said rapidly dividing cell is a tumor cell.
3. The method of claim 1, wherein the agent comprises a H3T3A mutant protein.
4. The method of claim 1, wherein the agent comprises a H3T3D mutant protein.
5. The method of claim 1 further comprising administering a chemotherapeutic agent distinct from the agent that reduces phosphorylation.
6. The method of claim 5, wherein said chemotherapeutic agent comprises radiotherapy or a cell death-inducing agent.
7. A method of inhibiting tumor growth comprising: contacting a tumor cell with an agent that reduces phosphorylation at threonine 3 of histone 3 (H3T3P), thereby inhibiting tumor growth wherein the agent that reduces phosphorylation of H3T3P comprises an H3T3A mutant protein or an H3T3D mutant protein.
8. The method of claim 1 wherein the rapidly dividing cell is a hematological malignancy.
9. The method of claim 7, wherein the agent comprises a H3T3A mutant protein.
10. The method of claim 7, wherein the agent comprises a H3T3D mutant protein.
11. The method of claim 7 wherein the agent is administered to a subject.
12. The method of claim 10 wherein the subject is a human.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1) The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)
(21)
(22)
(23)
(24)
(25)
(26)
(27)
(28)
(29)
(30)
(31)
(32)
(33)
DETAILED DESCRIPTION
(34) The invention is based, at least in part, on the surprising discovery that histone H3 Thr 3 phosphorylation regulates asymmetric H3 inheritance and male germline activity in Drosophila and that an H3T3A mutant protein efficiently reduces H3T3P and causes increased cell death of rapidly-dividing cells. The methods described herein introduce a point mutation of the Thr3 residue of the transgenic histone H3 protein to produce a mutant transgenic protein to reduce the post-translational modification of H3 (i.e., to reduce the H3T3 phosphorylation in rapidly dividing cells) to cause cell cycle arrest followed by cell death. Because the mutant transgenic protein effectively reduces Thr3 phosphorylation including endogenous H3, this mutant form acts dominant negatively. Specifically, as described in detail below, a transgene that carries a mutation that converts threonine 3 (Thr3 or T3) to the unphosphorylatable alanine (Ala or A) greatly reduces the phosphorylation at T3 of histone 3 (H3T3P) mark. As described herein, during male germline stem cell asymmetric division, H3T3P regulates asymmetric H3 inheritance and affects germ cell function.
(35) Cancer is one of the most prevalent diseases, accounting for 25% of all deaths in the United States (Siege et al., 2012 Cancer statistics, 2:10-29). Prior to the invention described herein, there was a pressing need to develop new strategies to inhibit rapidly dividing cancer cells. As described herein, the H3T3P mark is important for mitosis and the reduction of which leads to increased cell death in rapidly-dividing cells including cancer cells. As such, the methods described herein antagonize growth in rapidly dividing cells. For example, the compositions described herein are anti-cancer agents that are utilized in methods to reduce tumor cell growth.
(36) As described in detail below, histone H3 shows asymmetric distribution during Drosophila male germline stem cell (GSC) asymmetric division. Prior to the invention described herein, the molecular mechanism and the biological relevance underlying this phenomenon were unclear. Described herein are experiments that demonstrate that phosphorylation at threonine 3 of H3 (H3T3P) distinguishes preexisting versus newly synthesized H3 in mitotic GSCs. A mutation that converts T3 to the unphosphorylatable alanine reduces H3T3P and results in randomized H3 inheritance patterns. Reduction of H3T3P causes GSC maintenance and germline differentiation defects including germ cell loss and tumors. Expression of H3 with T3 changed to phosphor-mimic aspartic acid results in similar phenotypes, indicating tight temporal control of H3T3P. The results presented herein indicate that mitosis-specific H3T3P distinguishes sister chromatids enriched with distinct H3 proteins and coordinates their proper inheritance, which is important for proper activity of both daughter cells derived from GSC asymmetric division.
(37) Many types of adult stem cells undergo asymmetric cell division to generate a self-renewed stem cell and a daughter cell which will subsequently differentiate (Morrison et al., 2006 Nature 441, 1068; Betschinger et al., 2004 Curr Biol 14, R674; H. Clevers, 2005 Nat Genet 37, 1027; M. Inaba and Y. M. Yamashita, 2012 Cell Stem Cell 11, 461). During the asymmetric division of Drosophila male germline stem cell (GSC), the preexisting histone H3 is selectively segregated to the GSC, whereas the newly synthesized H3 is enriched in the differentiating daughter cell known as a gonialblast (GB) (
(38) During the asymmetric division of the Drosophila male germline stem cell (GSC), the pre-existing his-tone 3 (H3) is selectively segregated to the self-renewed GSC daughter cell whereas newly synthesized H3 is enriched in the differentiating daughter cell known as a gonialblast (GB) (Tran et al., 2012) (
(39) First, the cellular specificity exhibited by the H3 histone suggests that global asymmetric histone inheritance occurs uniquely in a cell-type (GSC) where the mother cell must divide to produce two daughter cells each with a unique cell fate. Because this asymmetry is not observed in symmetrically dividing GB cells, asymmetric histone inheritance was proposed to be a phenomenon specifically employed by GSCs to establish unique epigenetic identities in each of the two daughter cells. Second, a major difference between H3 and H3.3 is that H3 is incorporated to chromatin during DNA replication, while H3.3 variant is incorporated in a replication-independent manner. Because this asymmetric inheritance mode is specific to H3, a two-step model was proposed to explain asymmetric H3 inheritance: (1) prior to mitosis, pre-existing and newly synthesized H3 are differentially distributed on the two sets of sister chromatids, and (2) during mitosis, the set of sister chromatids containing pre-existing H3 is segregated to GSCs, while the set of sister chromatids enriched with newly synthesized H3 is segregated to the GB that differentiates (Tran et al., 2012, 2013) (
(40) As described herein, a mitosis-enriched H3T3P mark acts as a transient landmark that distinguishes sister chromatids with identical genetic code but different epigenetic information, shown as pre-existing H3-GFP and newly synthesized H3-mKO. By distinguishing sister chromatids containing different epigenetic information, H3T3P functions to allow these molecularly distinct sisters to be segregated and inherited differentially to the two daughter cells derived from one asymmetric cell division. The selective segregation of different populations of histones likely allows these two cells to assume distinct fates: self-renewal versus differentiation. Consequently, loss of proper epigenetic inheritance might lead to defects in both GSC maintenance and GB differentiation, suggesting that both cells need this active partitioning process to either LLremember or LLreset their molecular properties.
(41) As described in detail below, the temporal and spatial specificities of H3T3P make it a great candidate to regulate asymmetric sister chromatid segregation. First, H3T3P is only detectable from prophase to metaphase, the window of time during which the mitotic spindle actively tries to attach to chromatids through microtubule-kinetochore interactions. Second, the H3T3P signal is enriched at the peri-centro-meric region, where kinetochore components robustly crosstalk with chromatin-associate factors. Third, H3T3 shows a sequential order of phosphorylation, first appearing primarily on sister chromatids enriched with pre-existing H3 and then subsequently appearing on sister chromatids enriched with newly synthesized H3 as the GSC nears metaphase. The distinct temporal patterns shown by H3T3P are unique to GSCs and would allow the mitotic machinery to differentially recognize sister chromatids bearing distinct epigenetic information; an essential step necessary for proper segregation during asymmetric GSC division. Furthermore, the tight temporal control of H3T3 phosphorylation suggests that rather than serving as an inherited epigenetic signature, H3T3P may act as transient signaling mark to allow for the proper partitioning of H3. H3T3P needs to be under tight temporal control in order to ensure proper H3 inheritance and germline activity.
(42) As described herein, these studies have shown that H3T3P is indeed subject to stringent temporal controls during mitosis. The H3T3P mark is undetectable during G2 phase. Upon entry to mitosis, sister chromatids enriched with pre-existing H3-GFP histone begin to show H3T3 phosphorylation prior to sister chromatids enriched with newly synthesized H3-mKO. As the cell continues to progress toward metaphase, H3T3P signal begins to appear on sister chromatids enriched with newly synthesized H3-mKO. Such a tight regulation of H3T3P is compromised when levels of H3T3P are altered due to the incorporation of mutant H3T3A or H3T3D. Incorporation of the H3T3A mutant results in a significant decrease in the levels of H3T3P on sister chromatids throughout mitosis, such that neither sister becomes enriched with H3T3P as the GSC progresses toward metaphase. Conversely, incorporation of the H3T3D mutant would result in seemingly elevated levels of H3T3P early in mitosis. Although H3T3A and H3T3D act in different ways, both mutations significantly disrupt the highly regulated temporal patterns associated with H3T3 phos-phorylation, the result of which is randomized H3 inheritance patterns and germ cell defects in testes expressing either H3T3A or H3T3D.
(43) As described in detail below, to further evaluate the extent of H3T3A and H3T3D roles in the segregation of sister chromatids enriched with different populations of H3 during mitosis (
(44) This estimation is close to experimental data, as described herein, in both H3T3A- and H3T3D-expressing testes (
(45) If the temporal separation in the phosphorylation of H3T3 on epigenetically distinct sister chromatids facilitates their proper segregation and inheritance during asymmetric cell division, it is likely that mutations of the Haspin kinase will also affect the temporal control of H3T3 phosphorylation. In the context of H3T3A, where the levels of H3T3P are already reduced, a further decrease in H3T3P by reducing Haspin levels should limit the GSC's ability to distinguish between sister chromatids enriched with distinct H3. Indeed, haspin mutants enhance the phenotypes in nos>H3T3A testes. A different situation appears in the context of H3T3D where sister chromatids experience seemingly elevated levels of H3T3P at the start of mitosis. These elevated H3T3P levels may be exacerbated by the phosphorylation activity of the Haspin kinase. Therefore, it is conceivable that by halving the levels of the Haspin kinase, H3T3 phosphorylation should be reduced to a level more closely resembling wild-type. In this way, some of the temporal specificity that is lost in the H3T3D mutant is restored, resulting in suppression of the phenotypes observed in nos>H3T3D testes. An exciting topic for future study would be to further explore how exactly Haspin phosphorylates H3T3 in the context of chromatin and whether H3T3A and H3T3D mutations act synergistically or antagonistically in regulating asymmetric sister chromatids segregation through differential phosphorylation of a key histone residue.
(46) Also described herein is the potential connection between asymmetric histone inheritance and another phe-nomenon reported by several investigators: selective DNA strand segregation (reviewed by Evano and Tajbakhsh, 2013; Rando, 2007; Tajbakhsh and Gonzalez, 2009). Recent development of the chromosome orientation fluorescence in situ hybridization (CO-FISH) technique (Falconer et al., 2010) allows study of selective chromatid segregation at single-chromosome resolution. Using this technique in mouse satellite cells, it has been demonstrated that all chromosomes are segregated in a biased manner, such that pre-existing template DNA strands are preferentially retained in the daughter cell that retains stem cell identity. Interestingly, this biased segregation becomes randomized in progenitor non-stem cells (Rocheteau et al., 2012). Using CO-FISH in Drosophila male GSCs, sex chromosomes have been shown to segregate in a biased manner. Remarkably, sister chromatids from homologous autosomes have been shown to co-segregate independent of any specific strand preference (Yadlapalli and Yamashita, 2013). Thus, as described herein, there is a possible epigenetic source guiding the coordinated inheritance of Drosophila homologous autosomes. In many cases of biased inheritance, researchers have speculated about the existence of a molecular signature that would allow the cell to recognize and segregate sister chromatids bearing differential epigenetic information (Klar, 1994, 2007; Lansdorp, 2007; Rando, 2007; Yen-nek and Tajbakhsh, 2013). However, prior to the invention described herein, the identity of such a signature has remained elusive. Described herein is experimental evidence demonstrating that a tightly-controlled histone modification, H3T3P, is able to distinguish sister chromatids and coordinate their segregation.
(47) Epigenetic processes play important roles in regulating stem cell identity and activity. Failure to appropriately regulate epigenetic information may lead to abnormalities in stem cell behaviors, which underlie early progress toward diseases such as cancer and tissue degeneration. Priro to the invention described herein, due to the crucial role that such processes play in regulating cell identity and behavior, the field has long sought to understand whether and how stem cells maintain their epigenetic memory through many cell divisions. The results described herein suggest that the asymmetric segregation of pre-existing and newly synthesized H3-enriched chromosomes may function to determine distinct cell fates of GSCs versus differentiating daughter cells.
(48) Pharmaceutical Therapeutics
(49) The invention provides pharmaceutical compositions for use as a therapeutic. In one aspect, the composition is administered systemically, for example, formulated in a pharmaceutically-acceptable buffer such as physiological saline. Preferable routes of administration include, for example, instillation into the bladder, subcutaneous, intravenous, intraperitoneal, intramuscular, or intradermal injections that provide continuous, sustained levels of the composition in the patient. Treatment of human patients or other animals is carried out using a therapeutically effective amount of a therapeutic identified herein in a physiologically-acceptable carrier. Suitable carriers and their formulation are described, for example, in Remington's Pharmaceutical Sciences by E. W. Martin. The amount of the therapeutic agent to be administered varies depending upon the manner of administration, the age and body weight of the patient, and with the clinical symptoms of the neoplasia or infection. Generally, amounts will be in the range of those used for other agents used in the treatment of other diseases associated with neoplasia or infection, although in certain instances lower amounts will be needed because of the increased specificity of the compound. A compound is administered at a dosage that enhances an immune response of a subject, or that reduces the proliferation, survival, or invasiveness of a neoplastic cell as determined by a method known to one skilled in the art.
(50) Formulation of Pharmaceutical Compositions
(51) The administration of compositions for the treatment of a condition associated with endothelial dysfunction may be by any suitable means that results in a concentration of the therapeutic that, combined with other components, is effective in ameliorating, reducing, or stabilizing a condition associated with endothelial dysfunction. The composition may be contained in any appropriate amount in any suitable carrier substance, and is generally present in an amount of 1-95% by weight of the total weight of the composition. The composition may be provided in a dosage form that is suitable for parenteral (e.g., subcutaneously, intravenously, intramuscularly, intravesicularly or intraperitoneally) administration route. The pharmaceutical compositions may be formulated according to conventional pharmaceutical practice (see, e.g., Remington: The Science and Practice of Pharmacy (20th ed.), ed. A. R. Gennaro, Lippincott Williams & Wilkins, 2000 and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York).
(52) Human dosage amounts can initially be determined by extrapolating from the amount of compound used in mice or nonhuman primates, as a skilled artisan recognizes it is routine in the art to modify the dosage for humans compared to animal models. In certain embodiments it is envisioned that the dosage may vary from between about 0.1 g compound/kg body weight to about 5000 g compound/kg body weight; or from about 1 g/kg body weight to about 4000 g/kg body weight or from about 10 g/kg body weight to about 3000 g/kg body weight. In other embodiments this dose may be about 0.1, 0.3, 0.5, 1, 3, 5, 10, 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1600, 1700, 1800, 1900, 2000, 2500, 3000, 3500, 4000, 4500, or 5000 g/kg body weight. In other embodiments, it is envisaged that doses may be in the range of about 0.5 g compound/kg body weight to about 20 g compound/kg body weight. In other embodiments the doses may be about 0.5, 1, 3, 6, 10, or 20 mg/kg body weight. Of course, this dosage amount may be adjusted upward or downward, as is routinely done in such treatment protocols, depending on the results of the initial clinical trials and the needs of a particular patient.
(53) Pharmaceutical compositions are formulated with appropriate excipients into a pharmaceutical composition that, upon administration, releases the therapeutic in a controlled manner. Examples include single or multiple unit tablet or capsule compositions, oil solutions, suspensions, emulsions, microcapsules, microspheres, molecular complexes, nanoparticles, patches, and liposomes.
(54) Kits or Pharmaceutical Systems
(55) Pharmaceutical compositions may be assembled into kits or pharmaceutical systems for use in arresting cell cycle in rapidly dividing cells, e.g., cancer cells. Kits or pharmaceutical systems according to this aspect of the invention comprise a carrier means, such as a box, carton, tube, having in close confinement therein one or more container means, such as vials, tubes, ampoules, bottles, syringes, or bags. The kits or pharmaceutical systems of the invention may also comprise associated instructions for using the kit.
(56) As described in detail below, mitosis-specific epigenetic mark H3T3P distinguishes preexisting versus newly synthesized H3 to regulate their proper segregation during cell division. Mutating this threonine to either unphosphorylatable alanine or phosphor-mimic aspartic acid leads to mis-segregation of sister chromatids and dramatic germ cell defects including germline tumor and germ cell loss. The results presented herein highlight the importance of proper epigenetic inheritance in stem cells.
(57) The data presented herein demonstrate that a mitotic-specific H3T3P mark acts as an epigenetic landmark that distinguishes sister chromatids with identical genetic code, but different epigenetic information. Initiated by this recognition, different epigenetic information is inherited differentially to the two daughter cells derived from one asymmetric cell division, which allows these two cells to take distinct fates. Loss of this epigenetic inheritance might lead to defects in both GSC maintenance and GB differentiation, suggesting that both cells need this active partitioning process to either remember or reset their molecular properties.
(58) The practice of the present invention employs, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are well within the purview of the skilled artisan. Such techniques are explained fully in the literature, such as, Molecular Cloning: A Laboratory Manual, second edition (Sambrook, 1989); Oligonucleotide Synthesis (Gait, 1984); Animal Cell Culture (Freshney, 1987); Methods in Enzymology Handbook of Experimental Immunology (Weir, 1996); Gene Transfer Vectors for Mammalian Cells (Miller and Calos, 1987); Current Protocols in Molecular Biology (Ausubel, 1987); PCR: The Polymerase Chain Reaction, (Mullis, 1994); Current Protocols in Immunology (Coligan, 1991). These techniques are applicable to the production of the polynucleotides and polypeptides of the invention, and, as such, may be considered in making and practicing the invention. Particularly useful techniques for particular embodiments will be discussed in the sections that follow.
(59) The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the assay, screening, and therapeutic methods of the invention, and are not intended to limit the scope of what the inventors regard as their invention.
Example 1: Materials and Methods
(60) Fly Strains and Husbandry
(61) Fly stocks were raised using standard Bloomington medium at 18 C., 25 C., or 29 C. as noted. The following fly stocks were used: hs-flp on the X chromosome (Bloomington Stock Center BL-26902), haspin TRiP line (Bloomington Stock 35276), Df(haspin) (Bloomington Stock 7155), haspin.sup.M109386 (Bloomington Stock 53099), UAS-upd on the 2nd chromosome (Terry et al., 2006 Dev Biol, 294, 246), nos-Gal4 on the 2nd chromosome (Van Doren et al., 1998 Curr Biol 8, 243, bam-Gal4 on the 2nd chromosome (Eun et al., 2014 Science, 343, 1513).
(62) Generation of Fly Strains with Different Switchable Dual-Color Transgenes
(63) Standard procedures were used for all molecular cloning experiments. Enzymes used for plasmid construction were obtained from New England Biolabs (Beverly, Mass.). H3T3A and H3T3D point mutations were generated with quick change site-directed mutagenesis kit (Agilent Technologies 200521) according to manufacturer's instructions, based on the plasmids containing wild-type H3 sequences described in (Tran et al., 2012 Science 338, 679). Similar tagged histone proteins were used for previous studies (K. Ahmad and S. Henikoff, 2002 Mol Cell 9, 1191; K. Ahmad and S. Henikoff, 2001 J Cell Biol 153, 101). The H3T3A/D-mKO fusion sequences were recovered as an Xbal flanked fragment and were subsequently inserted into the Xbal site of the UASp plasmid to construct the UASp-H3T3A/D-mKO plasmid. The H3T3A/D-GFP fusion sequences were inserted to pBluescript-FRT-NheI-SV40 PolyA-FRT plasmid at the unique NheI site. The entire FRT-H3T3A/D-GFP-SV40 PolyA-FRT sequences were then subcloned into the UASp-H3T3A/D-mKO plasmid, as described previously (Tran et al., 2012 Science 338, 679), digested by NotI and BamHI (note: BglII and BamHI produce compatible cohesive ends). The final UASp plasmids were introduced to w.sup.1118 flies by P-element-mediated germline transformation (Bestgene Inc.).
(64) Heat Shock Scheme
(65) Flies with UASp-FRT-H3-GFP-PolyA-FRT-H-mKO or their mutant transgenes (H3T3A or H3T3D, e.g., UASp-FRT-H3T3A/D-GFP-PolyA-FRT-H3T3A/D-mKO) were paired with nos-Gal4 drivers. Flies were raised at 18 C. throughout development until adulthood to avoid pre-flip (Tran et al., 2012 Science 338, 679). Before heat shock, 0-3 day old males were transferred to vials that had been air dried for 24 hours. Vials were submerged with all air area (i.e., up to the plug) underneath water in a circulating 37 C. water bath for two hours and recovered in a 29 C. incubator for indicated time before dissection and immunostaining experiments.
(66) Temperature Shift Assay to Induce Germline Tumor in Adult Flies
(67) Flies with UASp-FRT-H3-GFP-PolyA-FRT-H-mKO or their mutant transgenes (H3T3A or H3T3D, e.g., UASp-FRT-H3T3A/D-GFP-PolyA-FRT-H3T3A/D-mKO) paired with either nos-Gal4 or bam-Gal4 driver were raised at 18 C. throughout development until adulthood. Newly enclosed males were collected and shifted to 29 C. for indicated time before dissection and immunostaining experiments.
(68) Immunostaining Experiments
(69) Immunofluorescence staining was performed using standard procedures (Tran et al., 2012 Science 338, 679; Hime et al., 1996 J Cell Sci 109 (Pt 12), 2779). Primary antibodies were mouse anti- spectrin (1:50, DSHB 3A9), mouse anti-Fas III (1:50, DSHB, 7G10), mouse anti-Armadillo (1:100; DSHB, N2 7A1 clone), rabbit anti-H3T3P (1:200, Millipore 05-746R), mouse anti-H3S10P (1:200; Millipore, #05-806), anti-CID (1:100; gift from Dr. Sylvia Erhardt, University of Heidelberg, Germany), and rabbit anti-Vasa (1:200; Santa Cruz SC-30210). Secondary antibodies were the Alexa Fluor-conjugated series (1:200; Molecular Probes). Lysotracker (Invitrogen L7528) was applied according to manufacturer recommendation. Images were taken using the Zeiss LSM 510 META or Zeiss LSM 700 Multiphoton confocal microscope with a 40 or 63 oil immersion objectives and processed using Adobe Photoshop software.
(70) EdU Incorporation to Label GSC-GB Pair at S-Phase
(71) EdU labeling of the GSC-GB pairs at S phase was performed using Click-iT EdU Alexa Fluor 647 Imaging Kit (Life Science C10640) according to manufacturer's instructions. Dissected testes were immediately incubated in S2 medium with 100 M EdU for 30 minutes at room temperature. The testes were subsequently fixed and proceed to primary antibodies (anti-FasIII, anti-a spectrin and anti-Vasa) incubation. Fluorophore conjugation to EdU was performed along manufacturer's instructions and followed by secondary antibodies incubation. The addition of EdU facilitates recognition of the GSC-GB pairs undergoing active DNA synthesis from those without EdU, which might be arrested due to the heat shock treatment. The cell cycle progression is important for the incorporation and segregation of preexisting versus newly synthesized H3.
(72) Lattice Light Sheet Microscopy
(73) Light sheet measurements were performed using a massively parallel linear array of non-diffracting beams that coherently interfere to create a 2D optical lattice confined to a single plane (Gao et al., 2014 Nat Protoc 9, 1083; B. C. Chen et al., 2014 Science 346, 1257998). This structured was then oscillated rapidly within the plane to create time-averaged uniform excitation in a 400 nm thick section across the entire field of view. The desired coherent pattern was generated using a spatial light modulator (SXGA-3DM, Forth Dimension Displays) that was conjugate to the sample plane, and that projected a binarized version of the desired pattern to be imaged at the sample. The fluorescence generated within the specimen by the light sheet was collected by an objective (Nikon, CFI Apo LWD 25XW, 1.1 NA, 2 mm WD) and then imaged on a fast camera (ORCA-flash4.0, Hamamatsu). Four lasers of excitations wavelengths 405 nm, 488 nm, 532 nm, and 640 nm were used, and a multi-band emission filter (Semrock, FF02-435/40-25, FF03-525/50-25, FF01-562/40-25, BLP01-647R-25) rejected the excitation wavelengths. The fixed sample was mounted on 5 mm coverslip through the light sheet at 50 ms exposure per 2D image. The excitation numerical aperture of light sheet is 0.42 for outer ring and 0.325 for inner one. The image voxel is 104104250 nm in x, y, z respectively. Multi-color experiments were performed by switching the color stack by stack. The 3D images obtained by sweeping the light sheet plane by plane through the specimen were deconvolved using a Richardson-Lucy algorithm.
(74) Immunoblot Experiments
(75) Histone H3 antibody (Abcam Cat # ab1791), H4 antibody (Abcam Cat # ab10158), and GFP antibody (Abcam Cat # ab13970) were used for immunoblot analyses. 15 testes were dissected in 1PBS and transferred to 1RIPA to prepare for the lysate of each sample. Novex 4-20% Tris-Glycine Mini Protein Gels (Life Science EC6025BOX) were used for SDS-PAGE. Rabbit anti-histone H3 (1:1000 Abcam ab1791) and Chicken anti-GFP (1:1000, Abcam ab13970) were used as primary antibodies. Goat anti-Chicken IgG (1:1000, Abcam ab97135) and goat anti-rabbit IgG (1:1000, Santa Cruz SC-2030) were used as secondary antibodies.
(76) Quantification of GFP and mKO Intensity
(77) No antibody was added to enhance either GFP or mKO signal. Values of GFP and mKO intensity were calculated using Image J software. DAPI signal was used to determine the area of nucleus for measuring both GFP and mKO fluorescent signals, the raw reading was subsequently adjusted by subtracting fluorescence signals in the hub region used as background in both GSC and GB nuclei and compared between each other.
(78) Male Fly Fertility Test
(79) For the fertility test, newly enclosed single nos>H3T3A-GFP males were mated with three y,w virgin females and at least ten crosses were set up simultaneously. Similar crosses were also made for the nos>H3-GFP control males. All crosses were kept at 29 C. and males were transferred into new vials with three y,w virgin females every five days until they were 20-day old. The progenies of each cross was counted for three days consecutively after they enclosed. Vials which did not contain all four flies alive (one male and three females) at the end of each 5-day mating period, were excluded from the counting and the plotting.
(80) Transcriptome Profiling (RNAseq) and Data Analyses
(81) Sample Isolation and mRNA Library Preparation
(82) Arcturus Picopure RNA isolation kit (Life Tecknologies, KIT0204) was utilized to prepare total RNA from dissected testis samples. Sequencing libraries were prepared by following the Illumina TruSeq RNA sample prep kit V2 (Illumina, RS-122-2001). Five H3T3A samples and two nos-Gal4; UAS-upd (nos>upd) (24, 42, 43) samples were sequenced on Illumina Mi-seq or Hi-seq 2500 sequencer. The Hi-seq 2500 runs were single-end 50 cycle sequencing, and the Mi-seq runs were pair-end 75*2 cycle sequencing. In the analysis, the pair-end reads were merged and treated as single-end. In addition, there are two transcriptome profiles from a previous published work (Gan et al., 2010 Cell Res 20, 763), one from wild-type testis tissue sample and one from bag-of-marbles (barn) mutant testis tissue sample. Thus, a total of nine samples/data were input for the transcriptome profiling analysis.
(83) The Alignment to Fly Genome and Gene Mapping
(84) The reads retrieved from multiple sequencing runs were examined by fastqc quality control software (bioinformatics.babraham.ac.uk/projects/fastqc/). The reads passed quality filter were mapped back to Drosophila melanogaster genome (dm3) (Flybase dmel_r5.43, as of January 2012, ftp.flybase.net/releases/FB2012_01/dmel_r5.43/). Bowtie aligner [version 0.12.7 (Langmead et al., 2009 Genome Biol 10, R25)] was utilized with the following configuration (-a --phred33-quals -n 2 -e 70-128 -m 1 --best -strata) which is basically allowing two mismatches and only one alignment site. Each read was then assigned into gene regions. The annotation for protein coding genes, ribosomal RNAs, tRNAs, snoRNA, snRNAss, pre_miRNAs, and other non-coding RNAs were retrieved from Flybase database (as of January 2012, ftp.flybase.net/releases/FB2012_01/dmel_r5.43/). The exons from different alternative splicing isoforms were merged to find the maximum genome coverage regions per gene. When a read is mapped to a region with more than one gene, i.e., one merged exon region overlapping with a non-coding gene, the count is split as equal possibilities into these two genes, half count for each. A matrix file with the number of reads assigned into each gene per sample was prepared for the following data analysis.
(85) Estimation of Transcription Level and Other Analysis
(86) The edgeR software package (Robinson et al., 2010 Bioinformatics 26, 139) in R was utilized to find the normalization factors for each sample with various sizes (by the TMM (Trimmed Mean of M value) and upper quantile normalization methods). The edgeR method models short reads into negative binomial distribution and estimates the biological replicate variance (dispersion). Tag-wise dispersion estimation was performed in H3T3A, nos-UPD, barn and wild-type four groupings of read count profiles. Quantity term corrected RPKM (cRPKM) was introduced by the formula: pseudo.alt*1e09/(length of merged transcripts)/(common.lib.size). The common.lib.size was calculated from the calcNormFactors function of edgeR, which performs TMM and upper quantile normalization methods and set a reference library. The pseudo.alt contains read counts after normalization across the input multiple profiles. The pseudo.alt was calculated by edgeR using quantile normalization and maximum likelihood method. The pseudo.alt contains pseudo read counts after correcting the library size and composition difference.
(87) After cRPKM calculation, gene expression levels per sample were pair-wisely compared with spearman correlation (correlation coefficient rho). A pair-wise inter-profile distance was defined as (1-rho) and set up a distance matrix. A dimension reduction method, multidimensional scaling in R (stat.ethz.ch/R-manual/R-devel/library/stats/html/cmdscale.html), was utilized to visualize the global similarity relationship among the nine samples (five nos>H3T3A samples, two nos>upd samples, one barn sample and one wild-type sample), as shown in
(88) In order to identify aberrant gene expression in nos>H3T3A testes, similarity among all nos>H3T3A samples is observed by hierarchical clustering. Kmeans method was utilized, with log.sub.2 transformation and Z score scaling. A Venn diagram shown in
Example 2: Histone H3 Thr 3 Phosphorylation Regulates Asymmetric H3 Inheritance and Male Germline Activity in Drosophila
(89) Described herein is a two-step model to explain this asymmetric H3 inheritance. First, prior to mitosis, preexisting and newly synthesized H3 are differentially distributed at the two sets of sister chromatids. Second, during mitosis, the set of sister chromatids containing preexisting H3 is segregated to GSCs, while the set of sister chromatids enriched with newly synthesized H3 is segregated to the GB that differentiates (
(90) To examine this model, a temporally controlled dual-color system was used to label preexisting H3 with GFP (green fluorescent protein) and newly synthesized H3 with mKO (monomeric Kusabira Orange) precisely (Tran et al., 2012 Science 338, 679). Asymmetric segregation of H3-GFP and H3-mKO were clearly visualized in anaphase and telophase GSCs imaged during the second mitosis following heat shock-induced H3-GFP- to H3-mKO-coding sequences switch (Tran et al., 2012 Science 338, 679). As described herein, H3-GFP and H3-mKO signals are already separable in a prophase GSC (
(91) The phosphorylation at threonine 3 of H3 (H3T3P) is enriched on mitotic chromosomes (Wang et al., 2010 Science 330, 231; Kelly et al., 2010 Science 330, 235; and Yamagishi et al., 2010 Science 330, 239) and has been proposed to function to ensure proper chromosome congression to the metaphase plate for reliable segregation of sister chromatids during anaphase (Dai et al., 2005 Genes Dev 19, 472). When immunostaining experiments were performed using an H3T3P-specific antibody, it was identified that H3-GFP (
(92) To understand the function of H3T3P in germ cells, fly lines were generated with an H3-GFP transgene carrying a point mutation that converts T3 to the unphosphorylatable Alanine (Ala or A, H3T3A). Expression of the H3T3A-GFP transgene in early germ cells by the nanos-Gal4 [nos-Gal4, (Van Doren et al., 1998 Curr Biol 8, 243)] driver greatly reduced the H3T3P signal (
(93) It was next identified whether H3T3A affects asymmetric H3 segregation during GSC asymmetric division using the dual-color labeling system (
(94) Expression of H3T3A in early germ cells (nos>H3T3A) also caused a spectrum of cellular defects after H3T3P is effectively reduced (
(95) These phenotypes in nos>H3T3A testes were specifically caused by expressing H3T3A in early-stage germ cells. Using a later-stage germline driver bam-Gal4 (C. Schulz et al., 2004 Genetics 167, 707; Eun et al., 2014 Science 343, 1513; and J. Cheng et al., 2008 Nature 456, 599) (
(96) Expression of another H3T3 mutant that converts T to the phosphor-mimic Aspartic acid (Asp or D) using the dual-color labeling system (
(97) The epigenetic writer that generates the H3T3P mark has been characterized as the Haspin kinase (Dai et al., 2005 Genes Dev 19, 472), loss-of-function phenotypes of the haspin gene were examined. When short hairpin RNA [shRNA, (Ni et al., 2011 Nat Methods 8, 405] was used to knock down haspin in early-stage germ cells using the nos-Gal4 driver, significant decrease of H3T3P in GSC was observed [arrow in
(98) To explore how Haspin may function with H3T3A or H3T3D in early-stage germ cells, it was examined whether halving the level of Haspin could modify either nos>H3T3A or nos>H3T3D phenotypes. Using a deficiency chromosome that uncovers the haspin gene region, it was identified that it substantially enhanced the nos>H3T3A phenotype (compare
(99) TABLE-US-00019 TABLE 1 Quantification of preexisting vs. newly synthesized H3, H3T3A and H3T3D in GSC-GB pairs for FIG. 3K and FIG. 16I. H3 H3T3A H3T3D GFP: mKO: GFP: mKO: GFP: mKO: Pair GSC/ GB/ Pair GSC/ GB/ Pair GSC/ GB/ # GB GSC # GB GSC # GB GSC 1 2.70 1.22 1 9.33 3.37 1 1.29 0.83 2 3.39 1.11 2 0.83 1.40 2 0.88 0.72 3 2.54 0.84 3 1.10 0.75 3 0.88 1.22 4 1.31 1.07 4 0.94 1.40 4 0.80 1.41 5 2.45 1.76 5 0.85 1.12 5 1.24 0.80 6 1.71 1.64 6 0.99 0.91 6 0.90 1.23 7 1.60 7.38 7 0.90 1.38 7 0.79 0.84 8 1.30 0.97 8 0.82 1.57 8 0.92 1.21 9 1.40 1.09 9 1.40 1.96 9 0.92 1.29 10 3.99 1.40 10 0.76 1.46 10 0.93 1.04 11 1.41 1.03 11 1.00 1.15 11 1.10 1.10 12 1.79 0.82 12 1.25 0.78 12 0.88 1.23 13 1.18 1.78 13 0.86 1.17 13 0.67 1.38 14 2.15 1.37 14 0.88 1.32 14 0.55 1.16 15 9.26 1.27 15 0.69 2.56 15 0.08 0.83 16 5.96 1.11 16 0.99 0.97 16 0.06 0.84 17 7.79 1.38 17 0.69 1.29 17 1.08 1.01 18 16.38 0.93 18 0.88 1.11 18 0.78 1.70 19 3.46 2.48 19 0.58 2.85 19 0.91 1.03 20 2.94 1.04 20 0.94 1.25 20 0.86 0.69 21 2.02 1.00 21 1.10 0.85 21 0.81 0.95 22 4.32 0.99 22 0.92 1.09 22 0.93 1.03 23 1.68 1.49 23 0.93 1.18 23 0.96 1.14 24 4.58 3.09 24 1.48 0.62 24 0.80 0.96 25 11.89 1.39 25 0.75 1.49 25 0.56 1.37 26 26.19 1.01 26 0.91 1.00 26 0.96 1.04 27 15.88 1.45 27 0.91 0.88 27 0.94 0.93 28 27.46 1.29 28 0.65 1.42 28 0.77 1.02 29 1.00 0.99 29 0.82 1.34 29 0.95 0.95 30 9.74 1.51 30 0.74 1.41 30 0.63 1.35 31 5.36 0.68 31 0.94 1.13 31 0.89 1.33 32 4.74 0.90 32 0.80 1.32 33 2.46 9.35 33 0.58 1.69 34 1.56 1.62 34 1.08 1.02 35 21.84 1.41 35 0.71 1.48 36 9.93 1.02 36 1.35 0.55 37 10.00 1.54 37 0.56 1.29 38 36.56 2.86 38 0.07 0.23 39 43.31 1.71 40 4.94 1.21 41 4.55 1.17 42 20.48 1.02 43 18.73 0.69 44 66.01 1.02 45 21.52 1.84 46 18.16 2.44 47 28.33 1.37 48 6.82 1.39 49 10.44 1.39 50 10.44 1.39 51 1.05 2.10 52 2.60 1.34 53 1.82 1.01 54 14.30 0.92 55 10.70 1.30
(100) TABLE-US-00020 TABLE 2A 100% Asymmetric Deposition X Y II III >1.5 Mbps <0.66 22 40 44 52 Sum: GFP GFP: GSC/GB 1 GSC 22 40 88 104 254 NA GB 22 40 88 104 0 2 GSC 22 40 88 104 214 5.35 GB 22 40 88 104 40 3 GSC 22 40 88 104 232 10.55 GB 22 40 88 104 22 4 GSC 22 40 88 104 192 3.10 GB 22 40 88 104 62 5 GSC 22 40 88 104 166 1.89 GB 22 40 88 104 88 6 GSC 22 40 88 104 126 0.98 GB 22 40 88 104 128 7 GSC 22 40 88 104 144 1.31 GB 22 40 88 104 110 8 GSC 22 40 88 104 104 0.69 GB 22 40 88 104 150 9 GSC 22 40 88 104 150 1.44 GB 22 40 88 104 104 10 GSC 22 40 88 104 110 0.76 GB 22 40 88 104 144 11 GSC 22 40 88 104 128 1.02 GB 22 40 88 104 126 12 GSC 22 40 88 104 88 0.53 GB 22 40 88 104 166 13 GSC 22 40 88 104 62 0.32 GB 22 40 88 104 192 14 GSC 22 40 88 104 22 0.09 GB 22 40 88 104 232 15 GSC 22 40 88 104 40 0.19 GB 22 40 88 104 214 16 GSC 22 40 88 104 0 NA GB 22 40 88 104 254 17 GSC 22 40 44/44 104 210 4.77 GB 22 40 44/44 104 44 18 GSC 22 40 44/44 104 170 2.02 GB 22 40 44/44 104 84 19 GSC 22 40 44/44 104 188 2.85 GB 22 40 44/44 104 66 20 GSC 22 40 44/44 104 148 1.40 GB 22 40 44/44 104 106 21 GSC 22 40 44/44 104 106 0.72 GB 22 40 44/44 104 148 22 GSC 22 40 44/44 104 66 0.35 GB 22 40 44/44 104 188 23 GSC 22 40 44/44 104 84 0.49 GB 22 40 44/44 104 170 24 GSC 22 40 44/44 104 44 0.21 GB 22 40 44/44 104 210 25 GSC 22 40 44/44 104 210 4.77 GB 22 40 44/44 104 44 26 GSC 22 40 44/44 104 170 2.02 GB 22 40 44/44 104 84 27 GSC 22 40 44/44 104 188 2.85 GB 22 40 44/44 104 66 28 GSC 22 40 44/44 104 148 1.40 GB 22 40 44/44 104 106 29 GSC 22 40 44/44 104 106 0.72 GB 22 40 44/44 104 148 30 GSC 22 40 44/44 104 66 0.35 GB 22 40 44/44 104 188 31 GSC 22 40 44/44 104 84 0.49 GB 22 40 44/44 104 170 32 GSC 22 40 44/44 104 44 0.21 GB 22 40 44/44 104 210 33 GSC 22 40 88 52/52 202 3.88 GB 22 40 88 52/52 52 34 GSC 22 40 88 52/52 162 1.76 GB 22 40 88 52/52 92 35 GSC 22 40 88 52/52 180 2.43 GB 22 40 88 52/52 74 36 GSC 22 40 88 52/52 140 1.23 GB 22 40 88 52/52 114 37 GSC 22 40 88 52/52 114 0.81 GB 22 40 88 52/52 140 38 GSC 22 40 88 52/52 74 0.41 GB 22 40 88 52/52 180 39 GSC 22 40 88 52/52 92 0.57 GB 22 40 88 52/52 162 40 GSC 22 40 88 52/52 52 0.26 GB 22 40 88 52/52 202 41 GSC 22 40 88 52/52 202 3.88 GB 22 40 88 52/52 52 42 GSC 22 40 88 52/52 162 1.76 GB 22 40 88 52/52 92 43 GSC 22 40 88 52/52 180 2.43 GB 22 40 88 52/52 74 44 GSC 22 40 88 52/52 140 1.23 GB 22 40 88 52/52 114 45 GSC 22 40 88 52/52 114 0.81 GB 22 40 88 52/52 140 46 GSC 22 40 88 52/52 74 0.41 GB 22 40 88 52/52 180 47 GSC 22 40 88 52/52 94 0.59 GB 22 40 88 52/52 160 48 GSC 22 40 88 52/52 52 0.26 GB 22 40 88 52/52 202 49 GSC 22 40 44/44 52/52 158 1.65 GB 22 40 44/44 52/52 96 50 GSC 22 40 44/44 52/52 118 0.87 GB 22 40 44/44 52/52 136 51 GSC 22 40 44/44 52/52 136 1.15 GB 22 40 44/44 52/52 118 52 GSC 22 40 44/44 52/52 96 0.61 GB 22 40 44/44 52/52 158 53 GSC 22 40 44/44 52/52 158 1.65 GB 22 40 44/44 52/52 96 54 GSC 22 40 44/44 52/52 118 0.87 GB 22 40 44/44 52/52 136 55 GSC 22 40 44/44 52/52 136 1.15 GB 22 40 44/44 52/52 118 56 GSC 22 40 44/44 52/52 96 0.61 GB 22 40 44/44 52/52 158 57 GSC 22 40 44/44 52/52 158 1.65 GB 22 40 44/44 52/52 96 58 GSC 22 40 44/44 52/52 118 0.87 GB 22 40 44/44 52/52 136 59 GSC 22 40 44/44 52/52 136 1.15 GB 22 40 44/44 52/52 118 60 GSC 22 40 44/44 52/52 96 0.61 GB 22 40 44/44 52/52 158 61 GSC 22 40 44/44 52/52 158 1.65 GB 22 40 44/44 52/52 96 62 GSC 22 40 44/44 52/52 118 0.87 GB 22 40 44/44 52/52 136 63 GSC 22 40 44/44 52/52 136 1.15 GB 22 40 44/44 52/52 118 64 GSC 22 40 44/44 52/52 96 0.61 GB 22 40 44/44 52/52 158
(101) TABLE-US-00021 Asymmetry Cut-off Asymmetry Symmetry (opposite) 1.5 21 (32.8%) 22 (34.4%) 21 (32.8%) 2 14 (21.9%) 36 (56.2%) 14 (21.9%) 2.5 10 (15.6%) 44 (68.8) 10 (15.6%) 3 8 (12.5%) 48 (75%) 8 (12.5%)
(102) TABLE-US-00022 TABLE 2B 80% Asymmetric Deposition 80% asymmetric deposition X Y II III X Y II III Mbps Mbps GFP: 22 40 44 52 22 40 44 52 Sum: GFP GSC/GB 1 GSC 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 203.2 4.00 GSC GSC GB 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 50.8 GB GB 2 GSC 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 179.2 2.40 GSC GSC GB 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 74.8 GB GB 3 GS 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 190 2.97 GSC GSC GB 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 64 GB GB 4 GSC 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 166 1.89 GSC GSC GB 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 88 GB GB 5 GSC 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 150.4 1.45 GSC GSC GB 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 103.6 GB GB 6 GSC 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 126.4 0.99 GSC GSC GB 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 127.6 GB GB 7 GSC 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 137.2 1.17 GSC GSC GB 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 116.8 GB GB 8 GSC 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 113.2 0.80 GSC GSC GB 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 140.8 GB GB 9 GSC 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 140.8 1.24 GSC GSC GB 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 113.2 GB GB 10 GSC 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 116.8 0.85 GSC GSC GB 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 137.2 GB GB 11 GSC 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 127.6 1.01 GSC GSC GB 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 126.4 GB GB 12 GSC 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 103.6 0.69 GSC GSC GB 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 150.4 GB GB 13 GSC 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 88 0.53 GSC GSC GB 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 166 GB GB 14 GSC 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 64 0.34 GSC GSC GB 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 190 GB GB 15 GSC 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 74.8 0.42 GSC GSC GB 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 179.2 GB GB 16 GSC 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 50.8 0.25 GSC GSC GB 80% 17.6 32 70.4 83.2 20% 4.4 8 17.6 20.8 203.2 GB GB 17 GSC 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 176.8 2.29 GSC GSC GB 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 77.2 GB GB 18 GSC 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 152.8 1.51 GSC GSC GB 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 101.2 GB GB 19 GSC 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 163.6 1.81 GSC GSC GB 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 90.4 GB GB 20 GSC 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 139.6 1.22 GSC GSC GB 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 114.4 GB GB 21 GSC 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 114.4 0.82 GSC GSC GB 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 139.6 GB GB 22 GSC 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 90.4 0.55 GSC GSC GB 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 163.6 GB GB 23 GSC 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 101.2 0.66 GSC GSC GB 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 152.8 GB GB 24 GSC 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 77.2 0.44 GSC GSC GB 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 176.8 GB GB 25 GSC 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 176.8 2.29 GSC GSC GB 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 77.2 GB GB 26 GSC 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 152.8 1.51 GSC GSC GB 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 101.2 GB GB 27 GSC 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 163.6 1.81 GSC GSC GB 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 90.4 GB GB 28 GSC 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 139.6 1.22 GSC GSC GB 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 114.4 GB GB 29 GSC 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 114.4 0.82 GSC GSC GB 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 139.6 GB GB 30 GSC 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 90.4 0.55 GSC GSC GB 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 163.6 GB GB 31 GSC 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 101.2 0.66 GSC GSC GB 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 152.8 GB GB 32 GSC 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 77.2 0.44 GSC GSC GB 80% 17.6 32 35.2/35.2 83.2 20% 4.4 8 8.8/8.8 20.8 176.8 GB GB 33 GSC 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 172 2.10 GSC GSC GB 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 82 GB GB 34 GSC 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 148 1.40 GSC GSC GB 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 106 GB GB 35 GSC 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 158.8 1.67 GSC GSC GB 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 95.2 GB GB 36 GSC 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 134.8 1.13 GSC GSC GB 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 119.2 GB GB 37 GSC 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 119.2 0.88 GSC GSC GB 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 134.8 GB GB 38 GSC 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 95.2 0.60 GSC GSC GB 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 158.8 GB GB 39 GSC 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 106 0.72 GSC GSC GB 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 148 GB GB 40 GSC 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 82 0.48 GSC GSC GB 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 172 GB GB 41 GSC 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 172 2.10 GSC GSC GB 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 82 GB GB 42 GSC 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 148 1.40 GSC GSC GB 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 106 GB GB 43 GSC 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 158.8 1.67 GSC GSC GB 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 95.2 GB GB 44 GSC 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 134.8 1.13 GSC GSC GB 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 119.2 GB GB 45 GSC 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 119.2 0.88 GSC GSC GB 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 134.8 GB GB 46 GSC 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 95.2 0.60 GSC GSC GB 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 158.8 GB GB 47 GSC 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 106 0.72 GSC GSC GB 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 148 GB GB 48 GSC 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 82 0.48 GSC GSC GB 80% 17.6 32 70.4 41.6/41.6 20% 4.4 8 17.6 10.4/10.4 172 GB GB 49 GSC 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 145.6 1.34 GSC GSC GB 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 108.8 GB GB 50 GSC 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 121.6 0.92 GSC GSC GB 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 132.4 GB GB 51 GSC 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 132.4 1.09 GSC GSC GB 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 121.6 GB GB 52 GSC 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 108.4 0.74 GSC GSC GB 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 145.6 GB GB 53 GSC 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 145.6 1.34 GSC GSC GB 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 108.4 GB GB 54 GSC 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 121.6 0.92 GSC GSC GB 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 132.4 GB GB 55 GSC 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 132.4 1.09 GSC GSC GB 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 121.6 GB GB 56 GSC 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 108.4 0.74 GSC GSC GB 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 145.6 GB GB 57 GSC 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 145.6 1.34 GSC GSC GB 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 108.4 GB GB 58 GSC 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 121.6 0.92 GSC GSC GB 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 132.4 GB GB 59 GSC 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 132.4 1.09 GSC GSC GB 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 121.6 GB GB 60 GSC 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 108.4 0.74 GSC GSC GB 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 145.6 GB GB 61 GSC 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 145.6 1.34 GSC GSC GB 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 108.4 GB GB 62 GSC 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 121.6 0.92 GSC GSC GB 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 132.4 GB GB 63 GSC 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 132.4 1.09 GSC GSC GB 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 121.6 GB GB 64 GSC 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 108.4 0.74 GSC GSC GB 80% 17.6 32 35.2/35.2 41.6/41.6 20% 4.4 8 8.8/8.8 10.4/10.4 145.6 GB GB
(103) TABLE-US-00023 Asymmetry Cut-off Asymmetry Symmetry (Inverted) Boder Line 1.5 12 34 12 (18.75%) 6 (9.38%) (18.75%) (53.13%)
Example 3: Expression of H3T3A Changes the Assymetric H3 Segregation Pattern in Mitotic GSCs
(104) Because expression of the H3T3A provides a loss-of-function condition for H3T3P, as described herein, it was examined whether asymmetric histone segregation is affected in H3T3A-expressing GSCs using the dual-color labeling strategy (
(105) Because expression of H3T3A changes H3 distribution patterns in post mitotic GSC-GB pairs (see
(106) The GFP distribution patterns were quantified in post-mitotic GSC-GB pairs in H3T3A-expressing testes (
Example 4: Expression of H3T3A Causes Several Germline Defects
(107) A spectrum of cellular defects could be detected in nos>H3T3A testes after the level of H3T3P is effectively reduced (
Example 5: Expression of H3T3A in Late-Stage Germ Cells or Somatic Cells does not Cause Germline Tumors
(108) The GSC loss, germline tumor and hub enlargement phenotypes in nos>H3T3A testes were specifically caused by expressing H3T3A in early-stage germ cells. A later-stage germline driver, bam-Gal4 (Cheng et al., 2008; Eun et al., 2014; Schulz et al., 2004) (
(109) In addition to GSCs, another type of adult stem cell residing in the Drosophila testis niche is the cyst stem cell (CySC), which, under normal conditions, is the only mitotically active somatic gonadal cell type (Dinardo et al., 2011). When a somatic cell-specific Tj-Gal4 driver (Tanentzapf et al., 2007) was used to express H3T3A, it is sufficient to reduce H3T3P signal specifically in CySCs (
Example 6: Expression of H3T3D in Early-, but Not Late-Stage, Germ Cells Leads to Randomized H3 Inheritance and Cellular Defects
(110) To further understand how H3T3P functions in GSCs, a different H3T3 mutant was expressed for which the T3 residue was converted to the phosphomimetic aspartic acid (D), under the hypothesis that such a mutation may disrupt the temporal order of H3T3 phosphorylation (
(111) In addition, both progenitor germline tumor (
(112) Since both reduction of H3T3P by expression of H3T3A and the mimicking of H3T3P by expression of H3T3D result in similar histone inheritance and germline defects, phosphorylation of H3T3 might require a tight temporal control during GSC mitosis. Therefore, expressing either the H3T3A or the H3T3D may lead to loss of this control and similar defects in histone inheritance patterns as well as abnormal germline activity.
OTHER EMBODIMENTS
(113) While the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
(114) The patent and scientific literature referred to herein establishes the knowledge that is available to those with skill in the art. All United States patents and published or unpublished United States patent applications cited herein are incorporated by reference. All published foreign patents and patent applications cited herein are hereby incorporated by reference. Genbank and NCBI submissions indicated by accession number cited herein are hereby incorporated by reference. All other published references, documents, manuscripts and scientific literature cited herein are hereby incorporated by reference.
(115) While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.